METTL3 and neoplasm: In a 2018 study, mutations in METTL14 or decreased expression of METTL3 resulted in decreased m6A methylation levels in endometrial tumours, and this decrease promoted the proliferation and tumour formation of EC cells by activating the AKT signalling pathway and its regulators PHLPP2 and mTORC2 (27).